NCT07242170 Supplementary Nerve Blocks Added to the Adductor Canal Block for Postoperative Pain Management in Primary Total Knee Arthroplasty: A Randomized Controlled Comparison of Sciatic, BiFeS, and IPACK Techniques
| NCT ID | NCT07242170 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erzincan University |
| Condition | Post Operative Analgesia |
| Study Type | INTERVENTIONAL |
| Enrollment | 102 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 102 participants in total. It began in 2025-11-01 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Postoperative pain following total knee arthroplasty (TKA) is a significant clinical problem that delays early mobilization, reduces patient satisfaction, and increases analgesic requirements. The adductor canal block (ACB), which aims to provide analgesia while preserving motor function, is widely used in postoperative pain management after TKA. However, clinical and anatomical studies have demonstrated that ACB is effective only in the anteromedial sensory innervation of the knee and does not adequately block pain originating from the posterior knee capsule. This limitation reduces analgesic effectiveness, particularly in patients with a prominent posterior pain component. The sciatic nerve block has long been considered the gold standard for managing posterior knee pain. However, due to disadvantages such as motor weakness and delayed rehabilitation, current pain management protocols increasingly favor motor-sparing and complementary approaches such as the Biceps Femoris Short Head (BiFeS) block and the Interspace Between the Popliteal Artery and the Capsule of the posterior Knee (IPACK) block for posterior knee analgesia. In light of this information, the aim of our study is to guide clinical practice by comparing the postoperative analgesic efficacy, motor function outcomes, and patient satisfaction associated with sciatic nerve, BiFeS, and IPACK block techniques-each administered as a supplement to the adductor canal block-in patients undergoing total knee arthroplasty, with the ultimate goal of determining the optimal block combination for postoperative pain control.
Eligibility Criteria
Inclusion Criteria: * Patients classified as American Society of Anesthesiologists (ASA) physical status I-III * Patients undergoing primary total knee arthroplasty * Patients undergoing unilateral total knee arthroplasty * Patients between 18 and 75 years of age Exclusion Criteria: * Patients classified as American Society of Anesthesiologists (ASA) physical status IV or higher * Patients undergoing revision total knee arthroplasty * Patients undergoing bilateral total knee arthroplasty * Patients with neuromuscular disease * Patients who decline to participate in the study * Patients with cognitive dysfunction * Patients with known drug allergies * Patients with a history of local anesthetic systemic toxicity * Patients with neurological dysfunction * Patients with bleeding diathesis * Pregnant patients
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07242170 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Post Operative Analgesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07242170 currently recruiting?
Yes, NCT07242170 is actively recruiting participants. Contact the research team at msomunkran@gmail.com for enrollment information.
Where is the NCT07242170 trial being conducted?
This trial is being conducted at Erzincan, Turkey (Türkiye).
Who is sponsoring the NCT07242170 clinical trial?
NCT07242170 is sponsored by Erzincan University. The trial plans to enroll 102 participants.